{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:18:05Z","timestamp":1785521885550,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"High Institute for Research and Education in Transfusion"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53340-7","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:14:43Z","timestamp":1778735683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined PD-1 and TIGIT blockade via siRNA enhances anti-leukemic T-cell function and promotes AML cell apoptosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Samira","family":"Anvari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedigheh","family":"Amini-Kafiabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"3","key":"53340_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-026-10104-z","volume":"26","author":"F Heydari","year":"2026","unstructured":"Heydari, F. et al. Beyond remission: The cardiotoxic and thrombotic shadow of AML chemotherapy. Cardiovasc. Toxicol. 26(3), 31 (2026).","journal-title":"Cardiovasc. Toxicol."},{"issue":"1","key":"53340_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-026-00744-w","volume":"15","author":"F Heydari","year":"2026","unstructured":"Heydari, F., Hamblin, M. R. & Naghinezhad, J. Hijacking the helpers: Platelet and neutrophil trafficking in AML and therapeutic exploitation. Exp. Hematol. Oncol. 15(1), 13 (2026).","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"53340_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4), 424\u2013447 (2017).","journal-title":"Blood"},{"key":"53340_CR4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA. Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA. Cancer J. Clin."},{"issue":"8","key":"53340_CR5","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s13346-022-01189-4","volume":"13","author":"A Dozzo","year":"2023","unstructured":"Dozzo, A. et al. Modelling acute myeloid leukemia (AML): What\u2019s new? A transition from the classical to the modern. Drug Deliv. Transl. Res. 13(8), 2110\u20132141 (2023).","journal-title":"Drug Deliv. Transl. Res."},{"issue":"8","key":"53340_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","volume":"127","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian, H. M., Kadia, T. M., DiNardo, C. D., Welch, M. A. & Ravandi, F. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer 127(8), 1186\u20131207 (2021).","journal-title":"Cancer"},{"issue":"3","key":"53340_CR7","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits, A. & Niroula, R. Acute myeloid leukemia: A review. R. I. Med. J. 103(3), 38\u201340 (2020).","journal-title":"R. I. Med. J."},{"key":"53340_CR8","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood-2023-179325","volume":"142","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. 1- and 5-year survival for adults with acute myeloid leukaemia and 30-day mortality after initial systemic anti-cancer therapy, with an exploration of factors associated with poorer outcomes: Data from a national registry in England, 2013\u20132020. Blood 142, 2846 (2023).","journal-title":"Blood"},{"issue":"4","key":"53340_CR9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago, L. & Gojo, I. Immune escape and immunotherapy of acute myeloid leukemia. J. Clin. Invest. 130(4), 1552\u20131564 (2020).","journal-title":"J. Clin. Invest."},{"issue":"4","key":"53340_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041944","volume":"22","author":"R Tabata","year":"2021","unstructured":"Tabata, R., Chi, S., Yuda, J. & Minami, Y. Emerging immunotherapy for acute myeloid leukemia. Int. J. Mol. Sci. 22(4), 1944 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"53340_CR11","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.3390\/cancers13246246","volume":"13","author":"A Aureli","year":"2021","unstructured":"Aureli, A. et al. Immunotherapy as a turning point in the treatment of acute myeloid leukemia. Cancers 13(24), 6246 (2021).","journal-title":"Cancers"},{"issue":"26","key":"53340_CR12","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood.2023019961","volume":"143","author":"J Vadakekolathu","year":"2024","unstructured":"Vadakekolathu, J. & Rutella, S. Escape from T-cell\u2013targeting immunotherapies in acute myeloid leukemia. Blood 143(26), 2689\u20132700 (2024).","journal-title":"Blood"},{"issue":"12","key":"53340_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123376","volume":"10","author":"F Hao","year":"2021","unstructured":"Hao, F., Sholy, C., Wang, C., Cao, M. & Kang, X. The role of T cell immunotherapy in acute myeloid leukemia. Cells 10(12), 3376 (2021).","journal-title":"Cells"},{"issue":"3","key":"53340_CR14","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.39","volume":"6","author":"L Gurska","year":"2023","unstructured":"Gurska, L. & Gritsman, K. Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia. Cancer Drug Resist. 6(3), 674 (2023).","journal-title":"Cancer Drug Resist."},{"key":"53340_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100709","volume":"45","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf, J. P., Shallis, R. M. & Zeidan, A. M. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1\/PD-L1 and CTLA-4 pathways. Blood Rev. 45, 100709 (2021).","journal-title":"Blood Rev."},{"issue":"4","key":"53340_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph14040288","volume":"14","author":"L Jimbu","year":"2021","unstructured":"Jimbu, L. et al. Is there a place for PD-1-PD-L blockade in acute myeloid leukemia?. Pharmaceuticals 14(4), 288 (2021).","journal-title":"Pharmaceuticals"},{"issue":"1","key":"53340_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00263-4","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang, X., Ma, L., Zhang, X., Huang, L. & Wei, J. Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp. Hematol. Oncol. 11(1), 11 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"53340_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686156","volume":"11","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. PD-1 and TIGIT are highly co-expressed on CD8(+) T cells in AML patient bone marrow. Front Oncol. 11, 686156 (2021).","journal-title":"Front Oncol."},{"issue":"3","key":"53340_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver, N. et al. Efficacy, safety, and biomarkers of response to Azacitidine and Nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study. Cancer Discov. 9(3), 370\u2013383 (2019).","journal-title":"Cancer Discov."},{"key":"53340_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004794","author":"F Brauneck","year":"2022","unstructured":"Brauneck, F. et al. TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-004794 (2022).","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"53340_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12288-022-01618-x","volume":"39","author":"ZA Malati","year":"2023","unstructured":"Malati, Z. A., Pourfathollah, A. A., Dabbaghi, R., Balagholi, S. & Javan, M. R. Evaluation of a new method of leukocyte extractions from the leukoreduction filter. Indian J. Hematol. Blood Transfus. 39(3), 478\u2013486 (2023).","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"1","key":"53340_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97584-1","volume":"15","author":"A Moazzeni","year":"2025","unstructured":"Moazzeni, A., Kheirandish, M., Khamisipour, G., Rahbarizadeh, F. & Pourfathollah, A. A. Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy. Sci. Rep. 15(1), 12755 (2025).","journal-title":"Sci. Rep."},{"issue":"4","key":"53340_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1537-2995.2006.00772.x","volume":"46","author":"S N\u00e9ron","year":"2006","unstructured":"N\u00e9ron, S., Dussault, N. & Racine, C. Whole-blood leukoreduction filters are a source for cryopreserved cells for phenotypic and functional investigations on peripheral blood lymphocytes. Transfusion 46(4), 537\u2013544 (2006).","journal-title":"Transfusion"},{"issue":"1","key":"53340_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-80118-6","volume":"14","author":"J Naghinezhad","year":"2024","unstructured":"Naghinezhad, J. et al. Designing a linear accelerator-based \u201cX irradiation system\u201d for platelet products: An efficient, safe, accessible and cost-effective alternative for conventional X- or gamma irradiators. Sci. Rep. 14(1), 28363 (2024).","journal-title":"Sci. Rep."},{"key":"53340_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694055","volume":"12","author":"B Shibru","year":"2021","unstructured":"Shibru, B. et al. Detection of immune checkpoint receptors\u2013A current challenge in clinical flow cytometry. Front. Immunol. 12, 694055 (2021).","journal-title":"Front. Immunol."},{"key":"53340_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03039","volume":"10","author":"F Winkler","year":"2020","unstructured":"Winkler, F. & Bengsch, B. Use of mass cytometry to profile human T cell exhaustion. Front. Immunol. 10, 3039 (2020).","journal-title":"Front. Immunol."},{"issue":"1","key":"53340_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85329-z","volume":"15","author":"MH Ashoub","year":"2025","unstructured":"Ashoub, M. H. et al. siRNA-mediated inhibition of hTERT enhances the effects of curcumin in promoting cell death in precursor-B acute lymphoblastic leukemia cells: An in silico and in vitro study. Sci. Rep. 15(1), 3083 (2025).","journal-title":"Sci. Rep."},{"issue":"4","key":"53340_CR28","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s10528-023-10565-9","volume":"62","author":"F Yari","year":"2024","unstructured":"Yari, F. et al. Differential expression of the hTERT gene in umbilical cord-derived mesenchymal stem cells cocultured with B cell precursor leukemia cell microparticles or CD41+\/CD61+ platelet microparticles. Biochem. Genet. 62(4), 2796\u20132809 (2024).","journal-title":"Biochem. Genet."},{"key":"53340_CR29","first-page":"68","volume":"37","author":"J Naghinezhad","year":"2023","unstructured":"Naghinezhad, J. et al. Expression of DR4, DR5, FAS, caspase-8 and DDIAS genes in AML patients. Med. J. Islam Repub. Iran 37, 68 (2023).","journal-title":"Med. J. Islam Repub. Iran"},{"issue":"23","key":"53340_CR30","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.4161\/cc.22135","volume":"11","author":"N Patsoukis","year":"2012","unstructured":"Patsoukis, N., Sari, D. & Boussiotis, V. A. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 11(23), 4305\u20134309 (2012).","journal-title":"Cell Cycle"},{"issue":"104","key":"53340_CR31","first-page":"62","volume":"3","author":"J Naghinezhad","year":"2019","unstructured":"Naghinezhad, J. PI3K\/AKT\/mTOR pathway in ATLL: From basic biology to preclinical study. J. Cell Mol. Pharmacol. 3(104), 62\u201364 (2019).","journal-title":"J. Cell Mol. Pharmacol."},{"issue":"12","key":"53340_CR32","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong, Y. et al. T-Cell Immunoglobulin and ITIM Domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin. Cancer Res. 22(12), 3057\u20133066 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"53340_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39731","volume":"10","author":"C-Y Wang","year":"2024","unstructured":"Wang, C.-Y. et al. Immunoediting in acute myeloid leukemia: Reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis. Heliyon 10(21), e39731 (2024).","journal-title":"Heliyon"},{"issue":"4","key":"53340_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.htct.2020.10.963","volume":"43","author":"S Ferdowsi","year":"2021","unstructured":"Ferdowsi, S., Abbasi-Malati, Z. & Pourfathollah, A. A. Leukocyte reduction filters as an alternative source of peripheral blood leukocytes for research. Hematol. Transfus. Cell Ther. 43(4), 494\u2013498 (2021).","journal-title":"Hematol. Transfus. Cell Ther."},{"issue":"8","key":"53340_CR35","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","volume":"98","author":"N Jyotsana","year":"2019","unstructured":"Jyotsana, N. et al. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Ann. Hematol. 98(8), 1905\u20131918 (2019).","journal-title":"Ann. Hematol."},{"issue":"1","key":"53340_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-025-00340-3","volume":"16","author":"J Naghinezhad","year":"2025","unstructured":"Naghinezhad, J., Moradpanah, S., Khodakarim, N., Hamblin, M. R. & Rezaeeyan, H. Nanodrug-based modulation of platelet\u2013leukocyte interactions in ovarian cancer: A new frontier in targeted therapy. Cancer Nanotechnol. 16(1), 37 (2025).","journal-title":"Cancer Nanotechnol."},{"key":"53340_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-025-00355-w","author":"J Naghinezhad","year":"2025","unstructured":"Naghinezhad, J. et al. Smart DNA hydrogels for post-surgical hemostasis and tumor recurrence prevention: Bridging bioengineering and clinical translation. Cancer Nanotechnol. https:\/\/doi.org\/10.1186\/s12645-025-00355-w (2025).","journal-title":"Cancer Nanotechnol."},{"issue":"1","key":"53340_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2278229","volume":"24","author":"S Huang","year":"2023","unstructured":"Huang, S. et al. Higher PD-1\/Tim-3 expression on IFN-\u03b3+ T cells is associated with poor prognosis in patients with acute myeloid leukemia. Cancer Biol. Ther. 24(1), 2278229 (2023).","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"53340_CR39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1261\/rna.25706","volume":"12","author":"AL Jackson","year":"2006","unstructured":"Jackson, A. L. et al. Widespread siRNA \u201coff-target\u201d transcript silencing mediated by seed region sequence complementarity. RNA 12(7), 1179\u20131187 (2006).","journal-title":"RNA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53340-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53340-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53340-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:08:36Z","timestamp":1785517716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53340-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53340"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53340-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Ethics Committee of Shariati Hospital, Tehran, Iran, approved the study with the approval number IR.TUMS.HORCSCT.REC.1402.028. All participants were provided written informed consent during the study. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23339"}}